170 related articles for article (PubMed ID: 32503882)
1. Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
Chan TS; Scaringella YS; Raymond K; Taub ME
Drug Metab Dispos; 2020 Aug; 48(8):690-697. PubMed ID: 32503882
[TBL] [Abstract][Full Text] [Related]
2. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes.
Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL
Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Interplay between Uptake Transport and CYP3A4 Induction in Micropatterned Cocultured Hepatocytes.
Moore A; Chothe PP; Tsao H; Hariparsad N
Drug Metab Dispos; 2016 Dec; 44(12):1910-1919. PubMed ID: 27655038
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
7. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
Smith S; Lyman M; Ma B; Tweedie D; Menzel K
Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
[TBL] [Abstract][Full Text] [Related]
8. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure.
Rowland A; Ruanglertboon W; van Dyk M; Wijayakumara D; Wood LS; Meech R; Mackenzie PI; Rodrigues AD; Marshall JC; Sorich MJ
Br J Clin Pharmacol; 2019 Jan; 85(1):216-226. PubMed ID: 30340248
[TBL] [Abstract][Full Text] [Related]
9. Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction.
Ly JQ; Wong S; Liu L; Li R; Messick K; Chang JH
Drug Metab Dispos; 2021 Jul; 49(7):540-547. PubMed ID: 33863817
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes.
Klammers F; Goetschi A; Ekiciler A; Walter I; Parrott N; Fowler S; Umehara K
Drug Metab Dispos; 2022 May; 50(5):566-575. PubMed ID: 35246464
[TBL] [Abstract][Full Text] [Related]
11. In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes.
Docci L; Klammers F; Ekiciler A; Molitor B; Umehara K; Walter I; Krähenbühl S; Parrott N; Fowler S
AAPS J; 2020 Oct; 22(6):131. PubMed ID: 33051808
[TBL] [Abstract][Full Text] [Related]
12. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance.
Williamson B; Harlfinger S; McGinnity DF
Drug Metab Dispos; 2020 Nov; 48(11):1137-1146. PubMed ID: 32847864
[TBL] [Abstract][Full Text] [Related]
14. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
[TBL] [Abstract][Full Text] [Related]
15. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries.
van Dyk M; Marshall JC; Sorich MJ; Wood LS; Rowland A
Eur J Clin Pharmacol; 2018 Jul; 74(7):913-920. PubMed ID: 29572563
[TBL] [Abstract][Full Text] [Related]
16. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
[TBL] [Abstract][Full Text] [Related]
17. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
18. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
Ishikawa Y; Akiyoshi T; Imaoka A; Ohtani H
Biopharm Drug Dispos; 2017 Oct; 38(7):420-425. PubMed ID: 28425104
[TBL] [Abstract][Full Text] [Related]
19. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
Shah SS; Sasaki K; Hayashi Y; Motoyama S; Helmi AR; Khalil WF; Shimoda M
J Vet Med Sci; 2009 Sep; 71(9):1151-9. PubMed ID: 19801894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
